Articles tagged with Prostate Cancer
Research identifies three SNPs in PSA gene promoter that increase serum PSA levels, suggesting genotyping may improve prostate cancer detection sensitivity. The findings suggest a lower cutoff value for PSA testing for men with reduced PSA promoter genotype.
A new study identified three genetic variants associated with a 30% increase in prostate-specific antigen (PSA) levels. The discovery could lead to more accurate testing and fewer unnecessary biopsies, particularly for black men who are at higher risk of developing prostate cancer.
Long-term, heavy smoking significantly increases prostate cancer risk in middle-aged men, with double the risk of aggressive forms. Current smokers also face a 40% higher risk compared to nonsmokers.
A new test using ProPSA detected prostate cancer at lower PSA levels, identifying more aggressive forms of the disease. The test improved detection of early aggressive cancer in men who may not have been caught until it was too late.
Researchers found that high zinc intake was associated with an increased risk of advanced prostate cancer, but not with lower doses. The studies also failed to find evidence of simian virus 40 (SV40) DNA in non-Hodgkin's lymphoma samples.
Researchers have identified a genetic marker, MSR1, that increases prostate cancer risk in African-American men. The study, which recruited over 400 black men from Flint, Mich., found that rare germ-line mutations were associated with an increased risk.
A new study by UT Southwestern finds that finasteride effectively reduces prostate cancer risk and improves symptoms in men with benign prostatic hyperplasia. The drug, already used to treat BPH, works by inhibiting the conversion of testosterone to dihydrotestosterone, which is involved in prostate cancer development.
Finasteride has been shown to prevent prostate cancer in both low-risk and high-risk men. However, those on finasteride were more likely to develop high-grade cancers.
The study showed that FDHT-PET detected osseous lesions in patients with advanced metastatic prostate cancer, confirming its utility in evaluating prostate cancer patients. The test also revealed the presence of additional lymph node lesions not identified by CT scans, suggesting its potential to predict response to hormone therapy.
FDHT PET detected 46 lesions, outperforming conventional methods, which identified 59. The agent rapidly absorbed in metastatic lesions indicating functioning androgen receptors. Notably, FDHT uptake reduced in patients starting testosterone therapy.
A new experimental imaging technique has been developed to detect prostate cancer metastases in abdominal lymph nodes. The technique uses advanced high-resolution MR imaging, computerized image analysis, and a novel contrast agent to identify malignant nodes with high accuracy.
Researchers found that increasing RKIP expression in metastatic prostate cancer cells decreased their invasiveness and reduced lung metastases in mice. The study suggests that RKIP may be a suppressor of prostate cancer metastasis, offering new targets for cancer control.
A study suggests that extending screening intervals could reduce lead-time bias and overdetection rates associated with prostate cancer screenings. The research estimates a potential 60-90% increase in prostate cancer incidence, highlighting the need to weigh benefits against risks.
Researchers discovered that a lost protein called PEDF can inhibit angiogenesis, a crucial process for tumor growth, in prostate cancer cells. Treatment with PEDF also triggered increased cell death in cancer cells, suggesting its potential as a new treatment option.
A study of over 78,000 women found that those who worked rotating night shifts for years had a 35% greater risk of developing colorectal cancer. Additionally, research on melanoma suggests two separate pathways may lead to its development, and polymorphisms in certain genes may be associated with prostate cancer risk.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.
A recent study found that whey protein increased glutathione levels in human prostate cells by up to 64%, potentially protecting against prostate cancer. Whey contains the amino acid cysteine, essential for producing glutathione, which helps control free radicals.
Researchers found that nearly half of men with elevated PSA levels had returned to normal levels after a year or more, making unnecessary biopsies possible. Repeating the PSA test after waiting at least six weeks may reduce unnecessary procedures and small incidental tumors.
Researchers discovered that 3,3'-diindolylmethane (DIM) inhibits the proliferation of human prostate cancer cells by acting as a powerful anti-androgen. DIM, found in cruciferous vegetables like broccoli, decreases PSA levels and blocks the effects of androgen on cancer cells.
Researchers identified a strong association between EZH2 and ECAD biomarkers and prostate cancer recurrence. Moderate or strong expression of EZH2 coupled with at most moderate expression of ECAD is most strongly associated with biochemical recurrence.
A UC Davis study found that a soy extract supplement reduced PSA levels in men with untreated prostate cancer. The study involved 62 men who received genistein concentrated polysaccharide for six months, resulting in an average decrease of 17% in PSA levels.
Blocking the activation of Stat5 in prostate cancer cells triggers extensive cell death, providing a new targeted therapeutic approach to manage cancer growth and metastasis. Prostate cancer is the second leading cause of cancer death in men, with approximately 220,900 new cases expected in the US in 2003.
Researchers have discovered that injecting herpes simplex virus vectors can deliver neurotrophic factors to damaged nerves, improving intracavernous pressure in rats. This concept could translate to humans, enabling gene therapy as a prophylactic treatment for men undergoing radical prostatectomy.
A multi-center study analyzing 2,056 prostate cancer patients found that metastatic disease carries a significant mortality rate and incurs substantial healthcare expenses. Patients with metastatic disease had ten times the death rate of those with localized disease, with $13,650 more in annual healthcare costs.
Researchers discovered that specific p53 mutations facilitate androgen-independent growth in human prostate cells, while another gene, Id-1, promotes tumor aggressiveness. These findings could lead to new therapeutic strategies for hormone-independent prostate cancer.
A new technique developed by Malins' laboratory uses Fourier transform-infrared spectroscopy to analyze DNA from prostate tumor biopsies, allowing doctors to identify patients at high risk for metastasis. This breakthrough enables more informed treatment decisions and potentially saves lives.
Researchers identified lifestyle factors that predict prostate cancer recurrence in treated patients. Patients with low body mass index, regular exercise, and annual screenings had lower risk of progression.
Researchers found that 11C-acetate PET scans were more sensitive than 18F-FDG PET scans in detecting recurrent prostate cancer. The study used 46 patients with detectable serum PSA, and the imaging procedures were conducted on the same day.
Researchers discovered a link between genetic markers and prostate cancer spread in African-American men. The study found that the ratio of MMP to E-cadherin accurately predicted cancer metastasis.
A $10 million grant will fund a new prostate cancer research consortium led by Emory University, comprising 13 universities from eight states. The consortium aims to identify new therapeutic targets for advanced prostate cancer treatment.
A new study by Dartmouth researchers finds that more American men are screened for prostate cancer than for colorectal cancer, contradicting scientific evidence. The study, which analyzed data from over 50,000 men, reveals a significant disparity in screening rates between the two cancers.
A study found that 75% of men aged 50 and older reported undergoing PSA testing, compared to 63% for colorectal cancer screening. The mismatch between screening rates highlights the need for better patient education on effective cancer tests.
A new study led by Queen's University aims to increase the sensitivity of prostate cancers to anti-cancer drugs using nitroglycerine. Researchers hope to develop a better understanding of how prostate cancer cells become resistant to chemotherapy, with potential applications for other cancers such as breast cancer.
The Prostate Cancer Series assesses the epidemiology of prostate cancer, highlighting the impact of genetic and environmental risk factors. Despite progress in understanding diet-related risks, familial clustering, and ethnic variation remain poorly understood, presenting opportunities for further research.
A Mayo Clinic phase II study of 42 patients with advanced androgen-independent prostate cancer found that green tea did not provide therapeutic benefit. The study showed no sustained decline in PSA levels, and high doses of green tea were associated with significant side effects.
A study by Dr. Michael Gaziano and colleagues found a significant link between greater height and increased risk of prostate cancer in men aged 50 and above, with risks increasing by 32% for those over 72 inches tall. However, no association was found between weight or body mass index and prostate cancer risk.
Researchers found the prevalence of overweight among Los Angeles County school children to be 20.6 percent, with higher rates among boys and Latinos. An email-based program for nutrition intervention was also shown to be effective in changing dietary behavior, with over 50% of participants reporting success.
Researchers found that selenium supplements reduced DNA damage in elderly male dogs' prostates, potentially benefiting aging prostate health. A separate study suggests a new retinoid treatment may prevent lung cancer in former smokers by restoring RAR-ß expression and reducing squamous metaplasia.
A recent study found that over 75% of participants took supplements regularly, with women using more supplements overall and men with medical conditions taking more supplements. The study suggests that healthcare providers need to educate patients on safe supplement use to prevent potential harm.
Researchers have found a promising combination therapy that may significantly improve treatment outcomes for patients with advanced prostate cancer. In a phase II clinical trial, the combination of calcitriol and docetaxel showed a higher PSA response rate compared to docetaxel alone.
Researchers found that a flaxseed-rich diet inhibited tumor growth and reduced aggression in genetically engineered mice. The study suggests that lignans in flaxseed could play a role in inhibiting prostate cancer progression by influencing estrogen and testosterone metabolism.
Researchers found that PC-SPES reduced the effectiveness of paclitaxel treatment in both androgen-sensitive and androgen-independent models of prostate carcinoma. Consumption of garlic, chives, and other allium vegetables may be associated with a reduced risk of prostate cancer.
The UCLA SPORE will focus on identifying new molecular targets for therapies and investigating nutritional strategies to prevent prostate cancer. Researchers will work together to develop targeted therapies that focus on what is broken in the cancer cell.
A new blood test has been developed to detect prostate cancer with high accuracy, helping identify men who need a biopsy and those who don't. The test correctly identified 36 of 38 prostate cancer cases, as well as 70 asymptomatic men with benign conditions.
Researchers have developed a test that analyzes protein patterns in blood serum samples to predict prostate cancer diagnosis. The technique proved effective in identifying 95% of cases and 78% of benign diseases, showing promise as a new tool for reducing unnecessary biopsies.
Researchers found that EZH2 expression was significantly higher in metastatic prostate cancer tissue compared to localized prostate cancer. A future test for high levels of EZH2 protein could serve as a red flag for physicians to identify men with the most aggressive form of the disease.
The initiative involves over 50 investigators in Seattle and Vancouver, B.C., aiming to develop improved therapies for men with recurrent or advanced disease. Prostate cancer affects one in six men, with an estimated 189,000 diagnoses this year and 30,200 deaths.
A new clinical trial is investigating the combination of high-dose calcitriol and docetaxel in treating advanced prostate cancer, with the goal of reducing PSA levels by 50% or more. The study builds on promising preliminary results from a previous Oregon Health & Science University trial.
A research team led by Wake Forest and Johns Hopkins universities found that mutations in the MSR1 gene are associated with an increased risk of aggressive prostate cancer, particularly in African-American men. The study identified seven potentially important mutations of the MSR1 gene, including one that leads to rapid metastasis.
Researchers have identified a genetic link between macrophage scavenger receptor-1 (MSR1) and increased risk of prostate cancer. MSR1 mutations were found in approximately 12.5% of African American men with prostate cancer, compared to 1.8% without the disease.
A recent analysis of eight PC-SPES lots revealed widespread contamination with indomethacin and diethylstilbestrol, two potent synthetic compounds that undermine the supplement's anticancer potency. The study suggests that the contaminated batches had significantly reduced anticancer activity.
A new study published in the Journal of Clinical Oncology found that a healthy diet does not significantly affect Prostate-Specific Antigen (PSA) levels over a relatively short period. The researchers believe that longer-term dietary effects on prostate cancer are still unknown.
A recent study of over 1,350 men found no correlation between a low-fat, high-fiber diet and reduced PSA levels over a four-year period. The study suggests that a healthy dietary pattern may still have an inhibitory effect on prostate cancer incidence despite the lack of impact on PSA levels.
Researchers at Cedars-Sinai Medical Center have found that a potent experimental drug called 2C4 slows tumor growth in both breast and prostate cancer tumors in mice, even when small amounts of HER-2/neu are expressed. The study's findings may lead to a new way to treat breast and prostate cancers.
A new study found that men with early-stage prostate cancer who follow a low-fat diet have half the risk of late-stage disease compared to those who consume more fat. Low-fat diets also reduced blood levels of testosterone, which fuels prostate growth and may contribute to cancer development.
Researchers at Michigan Medicine have discovered a new predictive marker, HIP1, associated with an increased risk of developing prostate and colon cancer. HIP1 levels were found to rise significantly in tumor cells, making it a potential target for therapy.
Researchers engineered a virus to target prostate-specific antigen, appearing as 'hot spots' in primary tumors and distant metastases. This method could deliver toxic treatments directly to prostate cancer cells, killing them while sparing surrounding healthy tissue.
The Prostate Interactive Educational System (PIES) is an interactive, computer-based program designed to provide comprehensive information tailored to the patient's preferences. The program will present disease and treatment information, a virtual support group, and allow patients to jot down notes in a virtual notebook.
Researchers will examine genes responsible for prostate cancer growth and identify potential diagnostic markers and therapeutic targets. The study aims to understand why prostate cancer spreads into bones, leading to a better understanding of this disease and potential treatments.
Researchers found that measuring Mcm5 levels in urine could detect bladder cancer with higher sensitivity than current tests. Additionally, a study linked effective DNA repair capacity to poorer survival rates in NSCLC patients treated with chemotherapy.